Featured Research

from universities, journals, and other organizations

Race a factor in mortality in heart attack patients on anti-clotting drug

Date:

June 18, 2014

Source:

Washington University School of Medicine

Summary:

The first genetic variations linked to race have been identified that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel after a heart attack. In particular, the team found that two DNA variants common in African Americans were associated with an increased risk of both bleeding and death. In Caucasians, a different variant was linked to additional heart attacks and a higher risk of death.

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

Related Articles

These variants increased patients' risk of dying in the year following a first heart attack, but they appeared to do so for different reasons depending on race, according to a study at Washington University School of Medicine in St. Louis.

In particular, the team found that two DNA variants common in African Americans were associated with an increased risk of both bleeding and death. In Caucasians, a different variant was linked to additional heart attacks and a higher risk of death.

The research is published June 17 in the American Heart Association journal Circulation: Cardiovascular Genetics.

The variations influence the way people metabolize clopidogrel and can alter its effectiveness. The blood-thinning drug commonly is prescribed after a heart attack to reduce the likelihood of another heart attack or a stroke.

"The research is provocative," said the study's first author, cardiologist Sharon Cresci, MD, assistant professor of medicine and of genetics. "Knowing about potential genetic differences based on race can help physicians tailor drugs to patients based on their genetic makeup."

Clopidogrel is metabolized in the liver, where it is turned into its active form via a group of enzymes called cytochrome P450, or CYP for short. Although clopidogrel is effective in many patients, earlier studies determined that some people metabolize the drug better than others.

Indeed, in 2010, the Food and Drug Administration added a "black box" warning to labels of clopidogrel after research that primarily involved Caucasians showed that people with a particular CYP genetic variant metabolized the drug poorly, which reduced the amount of the drug circulating in the blood. These patients had a higher risk of heart attack and stroke.

Additional studies showed that other CYP gene variants are linked to the rapid metabolism of clopidogrel and that patients with those variants had a higher risk of bleeding.

But it has not been clear until now that the effects of these particular gene variations can vary by race in patients taking clopidogrel after a heart attack.

For the study, the researchers analyzed CYP variants among 2,062 Caucasians and 670 African Americans who suffered heart attacks. Nearly 80 percent of the Caucasians and 65 percent of the African Americans were prescribed clopidogrel. The patients were enrolled in a major study known as TRIUMPH (Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health) conducted from 2005 to 2008 at 24 U.S. hospitals, including Barnes-Jewish Hospital in St. Louis.

Among patients taking clopidogrel, the one-year mortality rate for African Americans was 7.2 percent, compared with 3.6 percent for Caucasians.

Caucasians who carried the CYP2C19*2 variant, which has been linked to poor metabolism of the drug, had a higher rate of repeat heart attacks and death. The higher rate of heart attacks is consistent with the slower metabolism of clopidogrel.

However, among African Americans treated with clopidogrel, the CYP2C19*2 variant was not associated with a higher rate of death.

Rather, African Americans had higher rates of bleeding and death if they carried either of two other variants: CYP1A2*1C or CYP2C19*17, the latter of which has been associated with the rapid metabolism of clopidogrel. Among Caucasians on clopidogrel, neither variant increased the risk of death.

"This is very novel information that begs for more research," said cardiologist Richard G. Bach, MD, the study's senior author and an associate professor of medicine at Washington University.

Although genetic testing is available to identify CYP variants in a patient's DNA, these tests generally are not widely used by cardiologists. Results of the current study suggest this practice may need to be reconsidered.

"This research is an important addition to the field because previous studies looking at CYP gene variants and their effects on risks of repeat heart attacks, bleeding and death have included predominantly Caucasian patients of European ancestry," Cresci noted. "There is almost no data, until now, about these variants in African Americans."

Research examining how genetic variants alter the effectiveness of clopidogrel remains somewhat controversial, Bach said. Many physicians feel that before they can tailor medical therapy for heart attack patients, more data is needed to prove there is a clear link between genetic variants and negative health consequences and that tailoring therapy will improve patients' outcomes, he explained.

His hope is that additional research would provide more definitive conclusions to help physicians choose the best medications for patients after a heart attack and, ultimately, "to reduce the too-high rate of death and disability for patients after a heart attack," Bach said.

Cresci agreed, adding: "By focusing on genetic differences, we may be able to individualize therapies after heart attacks and achieve the best treatment for each patient."

Washington University School of Medicine. "Race a factor in mortality in heart attack patients on anti-clotting drug." ScienceDaily. ScienceDaily, 18 June 2014. <www.sciencedaily.com/releases/2014/06/140618100612.htm>.

Washington University School of Medicine. (2014, June 18). Race a factor in mortality in heart attack patients on anti-clotting drug. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2014/06/140618100612.htm

Washington University School of Medicine. "Race a factor in mortality in heart attack patients on anti-clotting drug." ScienceDaily. www.sciencedaily.com/releases/2014/06/140618100612.htm (accessed March 31, 2015).

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 31, 2015  In addition to their physical injuries, women who are victims of domestic violence are also at a greater risk of mental health problems such as depression and psychotic symptoms. "We studied the ... full story

Mar. 31, 2015  New research has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of ... full story

Mar. 31, 2015  As the United States faces transplant waiting lists that continue to grow longer over time, there is increasing debate about the proper way to incentivize living donations. Due to organ shortages, ... full story

Mar. 31, 2015  The most virulent strains of Streptococcus suis, the leading cause of bacterial meningitis in adult humans in parts of southeast Asia and in pigs around the world, are likely to have evolved and ... full story

Mar. 31, 2015  A unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome have been discovered, providing insights into the basis for cognitive ... full story

Mar. 31, 2015  Children who get a taste of their parents' wine now and then may be more likely than their peers to start drinking by high school, according to a new report. The findings are based on 561 Rhode ... full story

Mar. 31, 2015  Scientists have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects. The work sheds light on the natural ... full story

Mar. 30, 2015  Neuroscientists are taking inspiration from natural motor control to design new prosthetic devices that can better replace limb function. Researchers have tested a range of brain-controlled devices ... full story

Mar. 30, 2015  Scientists have found the genetic signature of enterovirus D68 in half of the California and Colorado children diagnosed with acute flaccid myelitis -- sudden, unexplained muscle weakness and ... full story

Mar. 30, 2015  The first study to investigate the relationship between eating fruit and vegetables containing pesticide residues and the quality of men's semen has shown a link with lower sperm counts and ... full story

Featured Videos

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015)  The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports.
Video provided by Reuters

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015)  Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17
Video provided by AFP

Related Stories

May 28, 2014  Thirty percent of patients who had just received a stent failed to fill their prescription for an anti-clotting drug within three days of hospital discharge. The risk of heart attack and death is ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.